Amira Naimi
Research Subjects
Amira Naimi has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Raphael Reher
Department of Pharmacy, University of Marburg, Marburg, Germany
2 shared publications - Christoph Ulbricht
Institute of Pharmaceutical Biology, University of Bonn, Nussallee 6, 53115 Bonn, Germany
1 shared publication - Daniel Hilger
Department of Pharmaceutical Chemistry, Philipps-University Marburg, Marburg, Germany
1 shared publication - Daniel Petras
University of California Riverside
1 shared publication - Evi Kostenis
Institute of Pharmaceutical Biology, University of Bonn, Bonn, Germany
1 shared publication - Gebhard F. X. Schertler
Center for Life Sciences, Paul Scherrer Institute, Villigen, Switzerland
1 shared publication
Latest Publications
- Open Access
Discovery of a Cell-Permeable Gi-Signaling Inhibitor
Heterotrimeric G proteins regulate diverse physiological processes, yet selective small molecule modulators for the Gα i subfamily remain scarce. Here, we employed native metabolomics to screen a fungal culture collection for G protein binders, which led to the discovery of N-hydroxyapiosporamide (NHAP), a fungal specialized metabolite that functionally inhibits Gi-signaling. NHAP selectively binds Gα i1 and diminishes Gα i1 -mediated GTP turnover in biochemical assays. In primary ventricular cardiomyocytes, NHAP largely reversed acetylcholine-induced negative inotropy, demonstrating functional Gi-signaling blockade in a physiological context without acute cytotoxicity. This work establishes NHAP as a first-in-class Gi-selective inhibitor, providing a cell-permeable chemical scaffold for the optimization of next-generation agents to control Gi-signaling in cell-based systems and, ultimately, to target Gα i1 -driven pathologies.
Open AccessDiscovery of a Cell-Permeable Gi-Signaling Inhibitor
Heterotrimeric G proteins regulate diverse physiological processes, yet selective small molecule modulators for the Gα i subfamily remain scarce. Here, we employed native metabolomics to screen a fungal culture collection for G protein binders, which led to the discovery of N-hydroxyapiosporamide (NHAP), a fungal specialized metabolite that functionally inhibits Gi-signaling. NHAP selectively binds Gα i1 and diminishes Gα i1 -mediated GTP turnover in biochemical assays. In primary ventricular cardiomyocytes, NHAP largely reversed acetylcholine-induced negative inotropy, demonstrating functional Gi-signaling blockade in a physiological context without acute cytotoxicity. This work establishes NHAP as a first-in-class Gi-selective inhibitor, providing a cell-permeable chemical scaffold for the optimization of next-generation agents to control Gi-signaling in cell-based systems and, ultimately, to target Gα i1 -driven pathologies.
- Open Access
- 1 April 2026
- Published by American Chemical Society (ACS) in Journal of Natural Products
- Vol. 89 (4) , 1148-1160
Native Metabolomics Unveils Suomilide Analogs with Potent Trypsin Inhibitory Activity
Cyanobacteria are well-known for their ability to produce a diverse array of serine protease inhibitors and thus are a promising source of pharmaceutical lead structures. Here, native metabolomics was employed with trypsin to rapidly screen whole cyanobacterial metabolomes and uncover new potent inhibitors. In combination with subsequent correlative LC-HR-MS/MS-based analysis, this led to the fast discovery of the well-characterized natural product family of suomilides from Nostoc sp. KVJ20 as highly potent trypsin inhibitors. Notably, two of the six putative binders were recognized as potential unknown analogs and thus were chosen for isolation and structural elucidation by means of 1D/2D NMR spectroscopy, Marfey's analysis, and bioinformatic investigations. This resulted in the identification of new suomilides G and H (1/2), which were isolated together with the known congeners suomilide B (3) and D (4). We also demonstrated that all four isolated suomilides inhibit trypsin at low nanomolar to high picomolar concentrations in a competitive bioassay, confirming the exceptional potency of this growing compound family as protease inhibitors.
- 1 April 2026
- Published by American Chemical Society (ACS) in Journal of Natural Products
- Vol. 89 (4) , 1148-1160
Open AccessNative Metabolomics Unveils Suomilide Analogs with Potent Trypsin Inhibitory Activity
Cyanobacteria are well-known for their ability to produce a diverse array of serine protease inhibitors and thus are a promising source of pharmaceutical lead structures. Here, native metabolomics was employed with trypsin to rapidly screen whole cyanobacterial metabolomes and uncover new potent inhibitors. In combination with subsequent correlative LC-HR-MS/MS-based analysis, this led to the fast discovery of the well-characterized natural product family of suomilides from Nostoc sp. KVJ20 as highly potent trypsin inhibitors. Notably, two of the six putative binders were recognized as potential unknown analogs and thus were chosen for isolation and structural elucidation by means of 1D/2D NMR spectroscopy, Marfey's analysis, and bioinformatic investigations. This resulted in the identification of new suomilides G and H (1/2), which were isolated together with the known congeners suomilide B (3) and D (4). We also demonstrated that all four isolated suomilides inhibit trypsin at low nanomolar to high picomolar concentrations in a competitive bioassay, confirming the exceptional potency of this growing compound family as protease inhibitors.